{"id":"apremilast-cc-10004","safety":{"commonSideEffects":[{"rate":"15–20","effect":"Diarrhea"},{"rate":"10–15","effect":"Nausea"},{"rate":"8–12","effect":"Headache"},{"rate":"5–10","effect":"Upper respiratory tract infection"},{"rate":"5–8","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL514800","moleculeType":"Small molecule","molecularWeight":"460.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE4, apremilast increases intracellular cAMP levels, which suppresses the production of pro-inflammatory cytokines (TNF-α, IL-2, IL-6, IFN-γ) and enhances anti-inflammatory mediators. This mechanism reduces immune cell activation and inflammatory responses in conditions characterized by excessive immune-mediated inflammation.","oneSentence":"Apremilast inhibits phosphodiesterase 4 (PDE4) to reduce inflammatory cytokine production and modulate immune cell function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:40.583Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Behçet's disease (oral ulcers)"}]},"trialDetails":[{"nctId":"NCT07325266","phase":"PHASE2","title":"Human Laboratory Study of Apremilast for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2026-04-01","conditions":"Alcohol Use Disorder, Alcohol Misuse","enrollment":100},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT04804553","phase":"PHASE3","title":"Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis","status":"RECRUITING","sponsor":"Amgen","startDate":"2022-03-17","conditions":"Active Juvenile Psoriatic Arthritis","enrollment":60},{"nctId":"NCT06324435","phase":"PHASE1","title":"Apremilast for Alcohol Use Disorder Treatment in Women and Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2024-05-08","conditions":"Alcohol Use Disorder","enrollment":10},{"nctId":"NCT07029529","phase":"PHASE2","title":"Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Alcohol Use Disorder","enrollment":120},{"nctId":"NCT06122649","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-11-27","conditions":"Plaque Psoriasis","enrollment":203},{"nctId":"NCT04175613","phase":"PHASE3","title":"A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-12-20","conditions":"Psoriasis","enrollment":160},{"nctId":"NCT05565560","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-01-25","conditions":"Plaque Psoriasis","enrollment":17},{"nctId":"NCT05767047","phase":"PHASE3","title":"A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis","status":"RECRUITING","sponsor":"Amgen","startDate":"2023-03-23","conditions":"Behçet's Disease, Juvenile Psoriatic Arthritis","enrollment":48},{"nctId":"NCT04528082","phase":"PHASE3","title":"Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease","status":"RECRUITING","sponsor":"Amgen","startDate":"2021-09-09","conditions":"Behçet Disease","enrollment":60},{"nctId":"NCT06088199","phase":"PHASE3","title":"A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-10-24","conditions":"Plaque Psoriasis","enrollment":51},{"nctId":"NCT05875714","phase":"PHASE2","title":"Apremilast for Erythema Multiforme","status":"COMPLETED","sponsor":"Robert Micheletti","startDate":"2022-01-13","conditions":"Erythema Multiforme","enrollment":8},{"nctId":"NCT03284879","phase":"","title":"Post-Marketing Surveillance Study of OTEZLA","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-09-05","conditions":"Psoriasis","enrollment":1086},{"nctId":"NCT03774875","phase":"PHASE4","title":"A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-03-28","conditions":"Psoriasis","enrollment":277},{"nctId":"NCT04908189","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-15","conditions":"Psoriatic Arthritis","enrollment":729},{"nctId":"NCT05601492","phase":"EARLY_PHASE1","title":"Adherence to Otezla","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2025-06","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT05174065","phase":"PHASE3","title":"Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-03-08","conditions":"Palmoplantar Pustulosis","enrollment":176},{"nctId":"NCT05863273","phase":"","title":"Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）","status":"COMPLETED","sponsor":"First Hospital of China Medical University","startDate":"2023-05-22","conditions":"Psoriasis","enrollment":360},{"nctId":"NCT06863493","phase":"PHASE2, PHASE3","title":"Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients","status":"NOT_YET_RECRUITING","sponsor":"SFA Therapeutics","startDate":"2025-06-01","conditions":"Psoriasis (PsO)","enrollment":125},{"nctId":"NCT03783026","phase":"PHASE4","title":"A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-02-06","conditions":"Psoriatic Arthritis","enrollment":123},{"nctId":"NCT02775500","phase":"","title":"Apremilast Pregnancy Exposure Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2014-11","conditions":"Psoriatic Arthritis, Psoriasis","enrollment":233},{"nctId":"NCT03701763","phase":"PHASE3","title":"Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-12-19","conditions":"Psoriasis","enrollment":245},{"nctId":"NCT03747939","phase":"PHASE4","title":"Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-12-31","conditions":"Arthritis, Psoriatic","enrollment":310},{"nctId":"NCT04057937","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-10-16","conditions":"Palmoplantaris Pustulosis","enrollment":90},{"nctId":"NCT03539419","phase":"","title":"Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-06-12","conditions":"Psoriasis","enrollment":153},{"nctId":"NCT03608657","phase":"","title":"Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-07-31","conditions":"Arthritis, Psoriatic","enrollment":102},{"nctId":"NCT03828045","phase":"","title":"A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-02-06","conditions":"Arthritis, Psoriatic","enrollment":119},{"nctId":"NCT03721172","phase":"PHASE3","title":"Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-03-11","conditions":"Psoriasis","enrollment":595},{"nctId":"NCT03777436","phase":"PHASE3","title":"An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-02-11","conditions":"Psoriasis","enrollment":289},{"nctId":"NCT04908475","phase":"PHASE4","title":"Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-06-09","conditions":"Psoriasis","enrollment":352},{"nctId":"NCT04306965","phase":"PHASE2","title":"Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2020-08-01","conditions":"Atopic Dermatitis","enrollment":10},{"nctId":"NCT03587194","phase":"PHASE4","title":"Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2018-07-23","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT04031027","phase":"","title":"A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-07-22","conditions":"Plaque Psoriasis","enrollment":184},{"nctId":"NCT02740218","phase":"","title":"A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-06-30","conditions":"Psoriasis","enrollment":610},{"nctId":"NCT06084663","phase":"PHASE3","title":"Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2023-02-15","conditions":"Psoriasis and Psoriatic Arthritis","enrollment":36},{"nctId":"NCT02684123","phase":"NA","title":"Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-02","conditions":"Alopecia Areata","enrollment":30},{"nctId":"NCT02875184","phase":"","title":"A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-06","conditions":"Arthritis, Psoriatic","enrollment":200},{"nctId":"NCT04811573","phase":"PHASE1","title":"A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-03-31","conditions":"Healthy","enrollment":20},{"nctId":"NCT02425826","phase":"PHASE4","title":"A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-04-20","conditions":"Parapsoriasis","enrollment":221},{"nctId":"NCT02144857","phase":"PHASE4","title":"Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-05-30","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT03656666","phase":"PHASE2","title":"The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2019-09-24","conditions":"Lichen Planus of Vulva, Female Genital Disease","enrollment":42},{"nctId":"NCT03442088","phase":"PHASE2","title":"Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2018-06-01","conditions":"Plaque Psoriasis","enrollment":28},{"nctId":"NCT03741933","phase":"PHASE4","title":"Apremilast and Moderate to Severe Chronic Hand Dermatitis","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2019-02-28","conditions":"Chronic Hand Dermatitis","enrollment":""},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT03082729","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis - Apremilast","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-04-24","conditions":"Psoriasis, Cardiovascular Diseases","enrollment":70},{"nctId":"NCT03175549","phase":"PHASE2","title":"Medication Development in Alcoholism: Apremilast Versus Placebo","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2017-11-01","conditions":"Alcohol Use Disorder","enrollment":51},{"nctId":"NCT04590586","phase":"PHASE3","title":"Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-24","conditions":"COVID-19","enrollment":515},{"nctId":"NCT03168256","phase":"PHASE3","title":"CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Can-Fite BioPharma","startDate":"2018-09-15","conditions":"Plaque Psoriasis","enrollment":528},{"nctId":"NCT01307423","phase":"PHASE3","title":"Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-12-09","conditions":"Psoriatic Arthritis","enrollment":529},{"nctId":"NCT01690299","phase":"PHASE3","title":"Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-10-01","conditions":"Psoriasis, Psoriatic Arthritis","enrollment":250},{"nctId":"NCT01232283","phase":"PHASE3","title":"Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-11-22","conditions":"Plaque Psoriasis","enrollment":413},{"nctId":"NCT01194219","phase":"PHASE3","title":"Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09-09","conditions":"Plaque Psoriasis","enrollment":844},{"nctId":"NCT04161456","phase":"PHASE2","title":"Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata","status":"COMPLETED","sponsor":"Dr. Frank Behrens","startDate":"2019-10-09","conditions":"Acne Conglobata","enrollment":1},{"nctId":"NCT02626793","phase":"","title":"A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-08-03","conditions":"Psoriasis","enrollment":391},{"nctId":"NCT03930186","phase":"PHASE3","title":"A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-17","conditions":"Plaque Psoriasis","enrollment":152},{"nctId":"NCT03757013","phase":"","title":"A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-09-25","conditions":"Psoriasis","enrollment":453},{"nctId":"NCT04572997","phase":"PHASE2","title":"Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)","status":"COMPLETED","sponsor":"Kristian Reich","startDate":"2018-11-29","conditions":"Palmoplantar Pustulosis","enrollment":21},{"nctId":"NCT02641353","phase":"PHASE1","title":"Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-01-05","conditions":"Healthy Volunteers","enrollment":34},{"nctId":"NCT02777554","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-08-17","conditions":"Healthy Volunteers","enrollment":144},{"nctId":"NCT02307513","phase":"PHASE3","title":"A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-12-30","conditions":"Behçet's Syndrome","enrollment":207},{"nctId":"NCT03239106","phase":"PHASE2","title":"A Study Examining the Medication Apremilast as Treatment for Chronic Itch","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-12-01","conditions":"Itch","enrollment":10},{"nctId":"NCT02802735","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-06-22","conditions":"Pharmacokinetics","enrollment":28},{"nctId":"NCT01561963","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Healthy Subjects","enrollment":21},{"nctId":"NCT02236988","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-01-07","conditions":"Healthy Volunteers","enrollment":80},{"nctId":"NCT01634178","phase":"PHASE1","title":"Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Healthy Volunteer","enrollment":46},{"nctId":"NCT01634191","phase":"PHASE1","title":"Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Healthy Volunteer","enrollment":36},{"nctId":"NCT00708916","phase":"PHASE1, PHASE2","title":"Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-06","conditions":"Discoid Lupus Erythematosus","enrollment":8},{"nctId":"NCT04555707","phase":"PHASE4","title":"The Maintenance Effect of Enstilar Foam in Combination With Otezla","status":"UNKNOWN","sponsor":"Derm Research, PLLC","startDate":"2020-06-24","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT03836885","phase":"PHASE2","title":"Apremilast - Oral Lichen Planus Trial","status":"WITHDRAWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-11-21","conditions":"Oral Lichen Planus","enrollment":""},{"nctId":"NCT00456092","phase":"PHASE2","title":"Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-03-05","conditions":"Psoriatic Arthritis","enrollment":204},{"nctId":"NCT00866359","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-08-01","conditions":"Behcet Syndrome","enrollment":111},{"nctId":"NCT01172938","phase":"PHASE3","title":"Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06-02","conditions":"Psoriatic Arthritis","enrollment":504},{"nctId":"NCT03123471","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-05-16","conditions":"Psoriasis","enrollment":303},{"nctId":"NCT01583374","phase":"PHASE3","title":"Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-02","conditions":"Ankylosing Spondyloarthritis","enrollment":490},{"nctId":"NCT01925768","phase":"PHASE3","title":"Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-09-04","conditions":"Psoriatic Arthritis","enrollment":219},{"nctId":"NCT01285310","phase":"PHASE2","title":"Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2010-12-09","conditions":"Rheumatoid Arthritis","enrollment":237},{"nctId":"NCT00521339","phase":"PHASE2","title":"Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-08-01","conditions":"Psoriasis-Type Psoriasis, Plaque-Type Psoriasis","enrollment":31},{"nctId":"NCT02087943","phase":"PHASE2","title":"Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06","conditions":"Dermatitis, Atopic Dermatitis","enrollment":191},{"nctId":"NCT02289417","phase":"PHASE2","title":"Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-01-08","conditions":"Ulcerative Colitis","enrollment":170},{"nctId":"NCT01988103","phase":"PHASE2","title":"Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-09","conditions":"Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica","enrollment":254},{"nctId":"NCT00773734","phase":"PHASE2","title":"Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-09-01","conditions":"Psoriasis, Plaque-type Psoriasis","enrollment":352},{"nctId":"NCT02576678","phase":"PHASE2","title":"A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-10-13","conditions":"Psoriasis","enrollment":42},{"nctId":"NCT01212770","phase":"PHASE3","title":"PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09-30","conditions":"Psoriatic Arthritis","enrollment":505},{"nctId":"NCT01212757","phase":"PHASE3","title":"PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09-27","conditions":"Psoriatic Arthritis","enrollment":488},{"nctId":"NCT03740516","phase":"","title":"Expanded Access for CC-10004","status":"NO_LONGER_AVAILABLE","sponsor":"Amgen","startDate":"","conditions":"Bechet's Disease","enrollment":""},{"nctId":"NCT03096990","phase":"","title":"A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-04-21","conditions":"Arthritis, Psoriatic","enrollment":106},{"nctId":"NCT03097003","phase":"","title":"A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-04-06","conditions":"Psoriasis","enrollment":124},{"nctId":"NCT00606450","phase":"PHASE2","title":"Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04-01","conditions":"Psoriasis","enrollment":260},{"nctId":"NCT00604682","phase":"PHASE2","title":"Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-01-01","conditions":"Psoriasis","enrollment":19},{"nctId":"NCT01393158","phase":"PHASE2","title":"Apremilast for Atopic Dermatitis - A Pilot Study in Adults","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2009-05","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT00944658","phase":"PHASE2","title":"Spondylitis Trial of Apremilast for Better Rheumatic Therapy","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2009-08","conditions":"Ankylosing Spondylitis","enrollment":38},{"nctId":"NCT03000309","phase":"PHASE4","title":"Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2016-12-29","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT03441789","phase":"PHASE4","title":"Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"L.H. Kircik, M.D.","startDate":"2017-09-18","conditions":"Plaque Psoriasis","enrollment":28},{"nctId":"NCT02400749","phase":"PHASE4","title":"Apremilast in Palmo-Plantar Psoriasis","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2015-05","conditions":"Palmo-plantar Psoriasis","enrollment":100},{"nctId":"NCT03049267","phase":"PHASE2","title":"Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis","status":"COMPLETED","sponsor":"M.B.A. van Doorn","startDate":"2017-02-02","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT03422640","phase":"PHASE4","title":"Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia","status":"UNKNOWN","sponsor":"Bellevue Dermatology","startDate":"2018-07-12","conditions":"Frontal Fibrosing Alopecia","enrollment":20},{"nctId":"NCT03553433","phase":"PHASE4","title":"Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2018-06","conditions":"Psoriasis of Scalp, Psoriasis Vulgaris","enrollment":90},{"nctId":"NCT00869089","phase":"PHASE2","title":"Safety and Efficacy of CC-10004 for Prurigo Nodularis","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-09","conditions":"Prurigo Nodularis","enrollment":5},{"nctId":"NCT02558361","phase":"PHASE4","title":"Treatment With Apremilast in Patients With Psoriatic Arthritis","status":"WITHDRAWN","sponsor":"University of South Florida","startDate":"2016-04","conditions":"Psoriatic Arthritis","enrollment":""},{"nctId":"NCT00814632","phase":"PHASE2","title":"CC-10004 For The Treatment Of Vulvodynia","status":"COMPLETED","sponsor":"Kenneth Peters, MD","startDate":"2008-12","conditions":"Vulvodynia","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}acetamide (S enantiomer)","Otezla"],"phase":"marketed","status":"active","brandName":"Apremilast (CC-10004)","genericName":"Apremilast (CC-10004)","companyName":"Virginia Clinical Research, Inc.","companyId":"virginia-clinical-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apremilast inhibits phosphodiesterase 4 (PDE4) to reduce inflammatory cytokine production and modulate immune cell function. Used for Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}